BioXcel Therapeutics, Inc. Q4 Loss Declines

BioXcel Therapeutics, Inc. (BTAI) announced Loss for fourth quarter of -$10.86 million

The company's bottom line came in at -$10.86 million, or -$3.57 per share. This compares with -$22.26 million, or -$12.09 per share, last year.

The company's revenue for the period fell 2.6% to $0.37 million from $0.38 million last year.

BioXcel Therapeutics, Inc. earnings at a glance (GAAP) :

-Earnings: -$10.86 Mln. vs. -$22.26 Mln. last year.
-EPS: -$3.57 vs. -$12.09 last year.
-Revenue: $0.37 Mln vs. $0.38 Mln last year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com